Objective. To evaluate the prevalence of atypical antipsychotic use in privately insured children and the diagnoses associated with treatment. Study design. Claims were used to conduct a retrospective cohort study of children aged 2 through 18 years in the Midwest, covered by private insurance between 2002 and 2005 (n = 172 766). The 1-year prevalence of children receiving atypical antipsychotics was determined along with associated diagnoses. Results. The 1-year prevalence of atypical antipsychotics ranged from 7.9 per 1000 in 2002 to 9.0 in 2005. The leading diagnoses were disruptive behavior disorders (67%), mood disorders (65%), and anxiety disorders (43%).The authors found that 75% of children on atypical antipsychotics had more than one psychiatric diagnosis. Conclusions. Atypical antipsychotic use is primarily seen in children who have multiple psychiatric diagnoses. Studies are needed to assess the long-term safety and effectiveness in such patients with multiple diagnoses.
Cooper WO, Arbogast PG, Ding H., et al. Trends in prescribing of antipsychotic medications for US children . Ambul Pediatr. 2006;6:79-83.
2.
Patel NC, Crismon ML, Hoagwood K., et al. Trends in the use of typical and atypical antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry . 2005;44:548-556.
3.
Correll CUAntipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry . 2008;47:9-20.
4.
Patel NC, Hariprasad M., Matias-Akthar M., et al. Body mass index and lipid profiles in hospitalized children and adolescents exposed to atypical antipsychotics. J Child Adolesc Psychopharmacol. 2007;17:303-311.
5.
Wonodi I., Reeves G., Carmichael D., et al. Tardive dyskinesia in children treated with atypical antipsychotic medications. Mov Disord. 2007;22:1777-1782.
6.
McNicholas F. , Motala F.Transient ischemic attach with risperidone and clonidine. J Am Acad Child Adolesc Psychiatry . 2007;46:1530-1531.
7.
Wieck A., Haddad PMAntipsychotic-induced hyperprolactinemia in women: pathophysiology, severity and consequences. Selective literature review. Br J Psychiatry.2003;182:199-204.
8.
Findling RL, Steiner H., Weller EBUse of antipsychotics in children and adolescents. J Clin Psychiatry. 2005;66:29-40.
9.
Patel NC, Kistler JS, James EB, et al. A retrospective analysis of the short-term effects of olanzapine and quetiapine on weight and body mass index in children and adolescents. Pharmacotherapy. 2004;24:825-830.
10.
Correl CU, Carlson HEEndocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry . 2006;45: 771-791.
11.
Harrison-Woolrych M., Garcia-Quiroga J., Ashton J., Herbison P.Safety and usage of atypical antipsychotic medicines in children: a nationwide prospective cohort study. Drug Saf. 2007;30:569-579.
12.
McIntyre RS , Jerrell JMMetabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents . Arch Pediatr Adolesc Med. 2008;162:929-935.
13.
Sikich L., Frazier JA, McClellan J., et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizoaffective disorder: findings from the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study. Am J Psychiatry. 2008;165:1420-1431.
14.
Sanford M., Keating GMAripiprazole: in adolescents with schizophrenia. Paediatr Drugs. 2007;9:419-423.
15.
Luby JL, Stalets M., Belden A.Psychotropic prescriptions in a sample including both healthy and mood and disruptive disordered preschoolers: relationships to diagnosis, impairment, prescriber type, and assessment methods. J Child Adolesc Psychopharmacol . 2007;17: 205-215.
16.
Nagaraj R., Singhi P., Malhi P.Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J Child Neurol. 2006;21:450-455.
17.
Tohen M., Kryzhanovskaya L., Carlson G., et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry. 2007;164:1547-1556.
18.
McClellan JMOlanzapine and pediatric bipolar disorder: evidence for efficacy and safety concerns. Am J Psychiatry . 2007;164:1462-1464.
19.
Sporn AL, Vermani A., Greenstein DK, et al. Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome. J Am Acad Child Adolesc Psychiatry. 2007;46:1349-1356.
20.
Kronenberger WG, Giauque AL, Lafata DE, Bohnstedt BN, Maxey LE, Dunn DWQuetiapine addition in methylphenidate treatment-resistant adolescents with comorbid ADHD, conduct/oppositional-defiant disorder, and aggression: a prospective, open-label study. J Child Adolesc Psychopharmacol. 2007;17:334-347.
21.
Snyder R., Turgay A., Aman M., et al. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry . 2002;41:1026-1036.
22.
Findling RL , Reed MD, O’Riordan MA, et al. A 26-week open-label study of quetiapine in children with conduct disorder. J Child Adolesc Psychopharmacol. 2007;17:1-9.
23.
Strawn JR, Delbello MPOlanzapine for the treatment of bipolar disorder in children and adolescents . Expert Opin Pharmacother. 2008;9:467-474.
24.
US Department of Health and Human Services.FDA approves risperdal for two psychiatric conditions in children and adolescents. FDA News. August 22, 2007. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108969.htm . Accessed July 27, 2009.
25.
US Department of Health and Human Services.FDA approves the first drug to treat irritability associated with autism, risperdal. FDA News. October 6, 2006. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108759.htm . Accessed July 27, 2009.
26.
Patel NC, Crismon ML, Shafer A.Diagnoses and antipsychotic treatment among youths in a public mental health system. Ann Pharmacother. 2006;40:205-211.
27.
Curtis LH, Masselink LE, stbye T., et al. Prevalence of atypical antipsychotic drug use among commercially insured youths in the United States. Arch Pediatr Adolesc Med. 2005;159:362-366.
28.
Rani F., Murray ML, Byrne PJ, Wong ICK.Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics . 2008;121:1002-1009.
29.
Martin A., Sherwin T., Stubbe D., et al. Use of multiple psychotropic drugs by Medicaid-insured and privately insured children. Psychiatr Serv. 2002;53:1508.
30.
Sturm R., Ringel JS, Andreyeva T.Geographic disparities in children’s mental health care. Pediatrics. 2003;112: e308-e315.
31.
Hermann RC, Yang D., Ettner SL, et al. Prescription of antipsychotic drugs by office-based physicians in the United States, 1989-1997. Psychiatr Serv. 2002;53:425-430.
32.
Cooper WO, Hickson GB, Fuchs C., et al. New users of antipsychotic medications among children enrolled in TennCare. Arch Pediatr Adolesc Med. 2004 ;158:753-759.
33.
Olfson M., Blanco C., Liu L., et al. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry . 2006;63:679-685.
34.
Guevara J., Lozano P., Wickizer T., Mell L., Gephart H.Psychotropic medication use in a population of children who have attention-deficit/hyperactivity disorder. Pediatrics. 2002;109:733-739.
35.
Mandell DS, Morales KH, Marcus SC, Stahmer AC, Doshi J., Polsky DEPsychotropic medication use among Medicaid-enrolled children with autism spectrum disorders. Pediatrics. 2008 ;121:e441-e448.
36.
dosReis S., Zito JM, Safer DJ, Gardner JF, Puccia KB, Owens PLMultiple psychotropic medication use for youths: a two-state comparison . J Child Adolesc Psychopharmacol. 2005;15:68-77.
37.
Zito JM, Safer DJ, Devadatta S., et al. Psychotropic medication patterns among youth in foster care . Pediatrics. 2008;121:e157-e163.
38.
Rappley MD, Eneli IU, Mullan PB, et al. Patterns of psychotropic medication use in very young children with attention-deficit hyperactivity disorder. J Dev Behav Pediatr. 2002;23:23-29.
39.
Bussing R., Levin GMMethamphetamine and fluoxetine treatment of a child with attention deficit hyperactivity disorder and obsessive-compulsive disorder. J Child Adolesc Psychopharmacol. 1993;3:53-58.
40.
Gammon GD, Brown TEFluoxetine and methylphenidate in combination for treatment of attention deficit disorder and co-morbid depressive disorder. J Child Adolesc Psychopharmacol. 1991;3:1-10.
41.
Parraga HC, Kelly DP, Parraga MI, Cochran MK, Maxim LTCombined psychostimulant and tricyclic antidepressant treatment of Tourette’s syndrome and comorbid disorders in children. J Child Adolesc Psychopharmacol. 1994;4:113-122.
42.
Findling RLOpen-label treatment of comorbid depression and attentional disorders with co-administration of serotonin re-uptake inhibitors and psychostimulants in children, adolescents, and adults: a case series. J Child Adolesc Psychopharmacol. 1996;6:165-175.
43.
Hawkridge S. , Stein DJ, Bouwer C.Combined pharmacotherapy for TS and OCD (letter) . J Am Acad Child Adolesc Psychiatry . 1996 ;35:703-704.
44.
Safer DJ, Zito JM, Dosreis S.Concomitant psychotropic medication for youths. Am J Psychiatry . 2003;160:438-439.
45.
Gerardin P. , Cohen D., Mazet P., et al. Drug treatment of conduct disorder in young people. Eur Neuropsychopharmacol . 2002;12:361-370.
46.
Glick ID, Murray SR, Vasudevan P., et al. Treatment with atypical antipsychotics: new indications and new populations. J Psychiatr Res. 2001;35:187-191.
47.
Cheng-Shannon J., McGough JJ, Pataki C., et al. Second-generation antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol . 2004;14:372-394.
48.
McCracken JT , McGough J., Shah B., et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2007;347:314-321.
49.
Shekelle P. , Maglione M., Bagley S., et al. Efficacy and comparative effectiveness of off-label use of atypical antipsychotics. Comparative effectiveness review No. 6. http://effectivehealthcare.ahrq.gov/repFiles/Atypical_Antipsychotics_Final_Report.pdf . Published January 2007. Accessed July 27, 2009 .
50.
Aman MG, De Smedt G., Derivan A., et al. Risperidone Disruptive Behavior Study Group.Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence . Am J Psychiatry. 2002;159:1337-1346.
51.
Croonenberghs J.Risperidone in children with disruptive behavior disorders: a 1-year, open-label study of 504 patients. J Am Acad Child Adolesc Psychiatry. 2005;44: 64-72.
